Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Dr Helen Blair

Newcastle AuthorsTitleYearFull text
Dr Hayden Bell
Dr Helen Blair
Mankaran Singh
Professor Anthony Moorman
Professor Olaf Heidenreich
et al.		Correction: Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia (Cancer Cell International, (2023), 23, 1, (202), 10.1186/s12935-023-03057-8)2025
Magretta Adiamah
Beth Poole
Dr Janet Lindsey
Dr Rebecca Hill
Dr Helen Blair
et al.		MYC-dependent upregulation of the de novo serine and glycine synthesis pathway is a targetable metabolic vulnerability in group 3 medulloblastoma2025
Dr Hayden Bell
Dr Helen Blair
Samantha Jepson Gosling
Dr Martin Galler
Dan Astley
et al.		Combination p53 activation and BCL-xL/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia2024
Dr Ricky Tirtakusuma
Dr Paul Milne
Dr Helen Blair
Yuzhe Shi
Dr Simon Bomken
et al.		Fusion transcripts are present in early progenitor cells in KMT2A-rearranged B-ALL2024
Sandeep Potluri
Dr Helen Blair
Polina Derevianko
Dan Coleman
Dr Anja Krippner-Heidenreich
et al.		Leukemic stem cells activate lineage inappropriate signalling pathways to promote their growth2024
Dan Coleman
Dr Helen Blair
Sandeep Potluri
Professor Olaf Heidenreich
Pharmacological inhibition of RAS overcomes FLT3 inhibitor resistance in FLT3-ITD+ AML through AP-1 and RUNX12024
Dr Sarah Fordham
Dr Wei-Yu Lin
Dr Helen Blair
Dr Claire Elstob
Dr Hayden Bell
et al.		Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia2023
Dr Paul Sinclair
Dr Ruth Cranston
Prahlad Raninga
Joanna Cheng
Rebecca Hanna
et al.		Disruption to the FOXO-PRDM1 axis resulting from deletions of chromosome 6 in acute lymphoblastic leukaemia2023
Dr Hayden Bell
Dr Helen Blair
Mankaran Singh
Professor Anthony Moorman
Professor Olaf Heidenreich
et al.		Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia2023
Dr Helen Blair
Dr Katarzyna Szoltysek
Rachel Cameron
Professor Olaf Heidenreich
The MLL-Menin Interaction is a Therapeutic Vulnerability in NUP98-rearranged AML2023
Aaron Wilson
Sean Hockney
Sharon Angel
Dr Helen Blair
Dr Deepali Pal
A human mesenchymal spheroid prototype to replace moderate severity animal procedures in leukaemia drug testing2022
Dr Jose Luis Marin-Rubio
Dr Maria Duenas Fadic
Dr Tiaan Heunis
Dr Abeer Dannoura
Dr Joe Inns
et al.		A Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Assay Identifies Nilotinib as an Inhibitor of Inflammation in Acute Myeloid Leukemia2022
Dr Ricky Tirtakusuma
Dr Katarzyna Szoltysek
Professor Vasily Grinev
Dr Sirintra Nakjang
Dr Daniel Williamson
et al.		Epigenetic regulator genes direct lineage switching in MLL/AF4 leukemia2022
Dr Deepali Pal
Dr Helen Blair
Sean Hockney
Dr Melanie Beckett
Mankaran Singh
et al.		hiPSC-derived bone marrow milieu identifies a clinically actionable driver of niche-mediated treatment resistance in leukemia2022
Dr Toni Pringle
Dr Corey Chan
Dr Saimir Luli
Dr Helen Blair
Dr Kenneth Rankin
et al.		Synthesis and In Vivo Evaluation of a Site-specifically Labeled Radioimmunoconjugate for Dual-Modal (PET/NIRF) Imaging of MT1-MMP in Sarcomas2022
1234